Maurice P, Glidewell O, Jacquillat C, Silver R T, Carey R, Pas A T, Cornell C J, Burningham R A, Nissen N I, Holland J F
Cancer. 1978 May;41(5):1658-63. doi: 10.1002/1097-0142(197805)41:5<1658::aid-cncr2820410502>3.0.co;2-i.
In May 1972, the Cancer and Leukemia Group B initiated a randomized study comparing the effectiveness of CCNU and methyl-CCNU in patients with advanced malignant lymphomas, including Hodgkin's disease (HD), lymphosarcoma (LYS) and reticulum cell sarcoma (RCS). A single dose of 100 mg/m2 of CCNU or 150 mg/m2 of methyl-CCNU was given orally every 6 weeks. In patients with leukopenia or thrombocytopenia, due to prior treatment, this dose was reduced to 70 mg/m2 of CCNU and 100 gm/m2 of methyl-CCNU. Of 109 evaluable patients, 60 received CCNU and 49 received methyl-CCNU. Response rates (complete and partial) to CCNU and methyl-CCNU were respectively 42% (14/33) and 15% (3/20) in HD, 21% (3/14) and 21% (3/14) in LYS, 15% (2/13) and 27% (4/15) in RCS. Responses to methyl-CCNU, but not to CCNU, were seen only in patients who developed significant hematologic toxicity. Responses to both drugs were generally of short duration due to the advanced stage of the disease. Renal, hepatic or neurological toxicity was not observed. In conclusion, CCNU proved to be superior to methyl-CCNU for the treatment of advanced HD. CCNU was also observed to be of higher activity in Hodgkin's than in non-Hodgkin's lymphomas.
1972年5月，癌症与白血病B组开展了一项随机研究，比较洛莫司汀（CCNU）和司莫司汀（甲基CCNU）对晚期恶性淋巴瘤患者的疗效，这些患者包括霍奇金病（HD）、淋巴肉瘤（LYS）和网状细胞肉瘤（RCS）。每6周口服单剂量的CCNU，剂量为100 mg/m²，或甲基CCNU，剂量为150 mg/m²。对于因先前治疗导致白细胞减少或血小板减少的患者，该剂量减至CCNU 70 mg/m²和甲基CCNU 100 mg/m²。在109例可评估患者中，60例接受CCNU治疗，49例接受甲基CCNU治疗。在HD中，CCNU和甲基CCNU的缓解率（完全缓解和部分缓解）分别为42%（14/33）和15%（3/20）；在LYS中分别为21%（3/14）和21%（3/14）；在RCS中分别为15%（2/13）和27%（4/15）。仅在出现显著血液学毒性的患者中观察到对甲基CCNU的反应，而未观察到对CCNU的反应。由于疾病处于晚期，对两种药物的反应通常持续时间较短。未观察到肾、肝或神经毒性。总之，CCNU被证明在治疗晚期HD方面优于甲基CCNU。还观察到CCNU在霍奇金淋巴瘤中的活性高于非霍奇金淋巴瘤。
